These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32967239)

  • 21. Deficiency of optineurin enhances osteoclast differentiation by attenuating the NRF2-mediated antioxidant response.
    Xue P; Hu X; Chang E; Wang L; Chen M; Wu TH; Lee DJ; Foster BL; Tseng HC; Ko CC
    Exp Mol Med; 2021 Apr; 53(4):667-680. PubMed ID: 33864025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dehydrocostus lactone inhibits NFATc1 via regulation of IKK, JNK, and Nrf2, thereby attenuating osteoclastogenesis.
    Lee HI; Lee GR; Lee J; Kim N; Kwon M; Kim HJ; Kim NY; Park JH; Jeong W
    BMB Rep; 2020 Apr; 53(4):218-222. PubMed ID: 31964469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
    Thummuri D; Naidu VGM; Chaudhari P
    J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-κB and p38 Pathways During Osteoclastogenesis.
    Lu D; Li J; Liu H; Foxa GE; Weaver K; Li J; Williams BO; Yang T
    J Bone Miner Res; 2018 Oct; 33(10):1773-1784. PubMed ID: 29750835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spi-C positively regulates RANKL-mediated osteoclast differentiation and function.
    Go EM; Oh JH; Park JH; Lee SY; Lee NK
    Exp Mol Med; 2020 Apr; 52(4):691-701. PubMed ID: 32341419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors.
    Lin J; Lee D; Choi Y; Lee SY
    Sci Signal; 2015 Jun; 8(379):ra54. PubMed ID: 26038599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-myc is required for osteoclast differentiation.
    Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
    J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nrf2 differentially regulates osteoclast and osteoblast differentiation for bone homeostasis.
    Wang L; Liang Y; Zhou X; Tian Y; Miao Z; Ko CC; Hu X
    Biochem Biophys Res Commun; 2023 Sep; 674():19-26. PubMed ID: 37393640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways.
    Sapkota M; Li L; Choi H; Gerwick WH; Soh Y
    Eur J Pharmacol; 2015 Dec; 769():100-9. PubMed ID: 26550952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.
    Cheng CP; Huang HS; Hsu YC; Sheu MJ; Chang DM
    J Clin Immunol; 2012 Aug; 32(4):762-77. PubMed ID: 22396044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice.
    Zhao D; Shu B; Wang C; Zhao Y; Cheng W; Sha N; Li C; Wang Q; Lu S; Wang Y
    J Cell Biochem; 2020 Jan; 121(1):152-164. PubMed ID: 31318102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
    Rahman MM; Bhattacharya A; Fernandes G
    J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo.
    Kukita A; Kukita T; Nagata K; Teramachi J; Li YJ; Yoshida H; Miyamoto H; Gay S; Pessler F; Shobuike T
    Arthritis Rheum; 2011 Sep; 63(9):2744-54. PubMed ID: 21590684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.